Traws Pharma Inc
TRAW2.180USD
-0.020-0.91%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
15.41MCap. mercado
0.18P/E TTM
Más Datos de Traws Pharma Inc Compañía
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Información de Traws Pharma Inc
Símbolo de cotizaciónTRAW
Nombre de la empresaTraws Pharma Inc
Fecha de salida a bolsaJul 25, 2013
Director ejecutivoDr. Iain D. Dukes, Ph.D.
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 25
Dirección12 Penns Trail
CiudadNEWTOWN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal18940
Teléfono12677593680
Sitio Webhttps://www.onconova.com/
Símbolo de cotizaciónTRAW
Fecha de salida a bolsaJul 25, 2013
Director ejecutivoDr. Iain D. Dukes, Ph.D.
Ejecutivos de Traws Pharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles Parker
Mr. Charles Parker
Chief Financial Officer
Chief Financial Officer
--
--
Ms. M. Teresa Shoemaker
Ms. M. Teresa Shoemaker
Independent Director
Independent Director
--
--
Dr. Werner Cautreels
Dr. Werner Cautreels
Director
Director
--
--
Dr. Trafford Clarke, Ph.D.
Dr. Trafford Clarke, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nikolay Savchuk, Ph.D.
Dr. Nikolay Savchuk, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
251.90K
--
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.19K
--
Mr. Jack E. Stover, CPA
Mr. Jack E. Stover, CPA
Independent Chairman of the Board
Independent Chairman of the Board
8.00
--
Dr. John Leaman, M.D.
Dr. John Leaman, M.D.
Independent Director
Independent Director
--
--
Dr. C. David Pauza, Ph.D.
Dr. C. David Pauza, Ph.D.
Chief Scientific Officer, Virology
Chief Scientific Officer, Virology
--
--
Dr. Robert Redfield, M.D.
Dr. Robert Redfield, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Symbio
2.73M
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Symbio
2.73M
0.00%
Estadísticas de accionistas
Actualizado: mié., 24 de sep
Actualizado: mié., 24 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Viriom Inc
8.50%
OrbiMed Advisors, LLC
8.50%
Squadron Capital Management LLC
5.90%
Adage Capital Management, L.P.
4.63%
Savchuk (Nikolay)
3.54%
Otro
68.94%
Accionistas
Accionistas
Proporción
Viriom Inc
8.50%
OrbiMed Advisors, LLC
8.50%
Squadron Capital Management LLC
5.90%
Adage Capital Management, L.P.
4.63%
Savchuk (Nikolay)
3.54%
Otro
68.94%
Tipos de accionistas
Accionistas
Proporción
Private Equity
8.50%
Corporation
8.50%
Investment Advisor
6.27%
Hedge Fund
6.25%
Individual Investor
6.12%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.02%
Otro
61.75%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
49
1.68M
23.63%
-79.24K
2025Q2
57
2.78M
49.98%
+92.22K
2025Q1
59
3.22M
71.94%
+1.74M
2024Q4
58
1.47M
44.66%
+775.47K
2024Q3
57
942.34K
34.05%
+834.58K
2024Q2
58
213.81K
16.43%
+135.65K
2024Q1
55
74.05K
8.78%
-3.08K
2023Q4
60
70.75K
8.42%
-22.28K
2023Q3
70
76.41K
9.11%
-47.84K
2023Q2
73
78.91K
9.41%
-30.66K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Viriom Inc
605.53K
8.57%
--
--
Apr 28, 2025
OrbiMed Advisors, LLC
605.53K
8.57%
--
--
Jun 30, 2025
Squadron Capital Management LLC
420.50K
5.95%
+420.50K
--
Sep 12, 2025
Adage Capital Management, L.P.
330.00K
4.67%
--
--
Jun 30, 2025
Savchuk (Nikolay)
251.90K
3.57%
+168.68K
+202.70%
Apr 28, 2025
Vestal Point Capital, LP
149.80K
2.12%
-25.20K
-14.40%
Jun 30, 2025
Cautreels (Werner C)
98.35K
1.39%
-6.00K
-5.75%
Apr 28, 2025
Dukes (Iain D)
81.19K
1.15%
-2.03K
-2.44%
Apr 28, 2025
Alyeska Investment Group, L.P.
52.63K
0.75%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
35.73K
0.51%
+2.35K
+7.03%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
Fecha
Tipo
Relación
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
Sep 17, 2024
Merger
25→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
May 20, 2021
Merger
15→1
